هذه الأخبار غير متوفرة باللغة العربية.
BUSINESS
Halozyme Therapeutics: Q4 Earnings Snapshot
▪
Halozyme Therapeutics posted a $141.6 million fourth quarter loss, or $1.20 per share, with an adjusted loss of 24 cents that missed analysts’ expectations for $2.15 in earnings. Revenue reached $451.8 million, edging past Wall Street’s $448.6 million forecast. For the year, the company reported profit of $316.9 million, or $2.56 per share, on $1.4 billion in revenue. Halozyme guided full year earnings of $7.75 to $8.25 per share and revenue of $1.71 billion to $1.81 billion.
Prepared by Christopher Adams and reviewed by editorial team.
Media Bias
- Articles Published:
- 7
- Right Leaning:
- 0
- Left Leaning:
- 0
- Neutral:
- 7
- Distribution:
- Left 0%, Center 100%, Right 0%
Coverage of Story:
From Left
No left-leaning sources found for this story.
From Center
Halozyme Therapeutics: Q4 Earnings Snapshot
9NEWS WTOP WHAS 11 Louisville WHAS 11 Louisville WHAS 11 Louisville WTOP WHAS 11 LouisvilleFrom Right
No right-leaning sources found for this story.
Comments